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Background. Liver is the commonest site formetastasis in patients with neuroendocrine tumour (NET). A vastmajority of treatment
strategies including liver directed nonsurgical therapy, liver directed surgical therapy, and nonliver directed therapy have been
proposed. In this study we aim to investigate the outcome of liver resection in neuroendocrine tumour liver metastases (NELM).
Method. 293 patients had hepatectomy for liver metastasis in our hospital between June 1996 and December 2010. Twelve patients
were diagnosed to have NET in their final pathology and their data were reviewed. Results. The median ages of the patients were
48.5 years (range 20–71 years). Eight of the patients received major hepatectomy. Four patients received minor hepatectomy. The
median operation time was 418minutes (range 195–660minutes).Themedian tumor size was 8.75 cm (range 0.9–21 cm).There was
no hospital mortality. The overall one-year and three-year survivals were 91.7% and 55.6%. The one-year and three-year disease-
free survivals were 33.3% and 16.7%. Conclusion. Hepatectomy is an effective and safe treatment for NELM. Reasonable outcome
on long term overall survival and disease-free survival can be achieved in this group of patients with a low morbidity rate.
1. Introduction
Neuroendocrine tumours (NETs) comprise a wide range
of neoplasm which originates from cells of nervous and
endocrine systems. The most common sites of the disease
include the small bowel, large bowel, and the pancreas. It can
also arise from other parts of the body. Liver is the most
common site of metastases for gastrointestinal NETs.
Upon the first diagnosis, 56%–93%patients were found to
have synchronous neuroendocrine liver metastases (NELM)
together with a primary tumour [1]. It was not uncommon
that the metastases involve both lobes of the liver with diffuse
manifestations. Only around 10% of the patients was eligible
for liver resection upon discovery [2]. Although liver resec-
tion was considered to be the most effective treatment for
NELM in terms of survival, not every patient was considered
for hepatectomy due to the potential complications and even
mortality. Unlike colorectal liver metastasis, hepatectomy for
NELM had not been supported by large scale studies. Many
published data involve small numbers of patients because
resectable NELMs are not common.
In this study, we aim to analyze outcome of liver resection
for NELMs with curative intentions.
2. Materials and Methods
From June 1996 to December 2010, 293 patients received
hepatectomy for liver metastases at Department of Surgery,
Queen Mary Hospital, The University of Hong Kong, Hong
Kong. Twelve patients with NET liver metastases were
included in the present study. All patients had liver resection
performed with the histological diagnosis of neuroendocrine
tumour livermetastases. Patientswere followedupby amulti-
disciplinary team that consisted of surgeons and oncologists.
Thiswas a retrospective designed study, but all the clinical
data had been collected prospectively in a computerized
data base recording the preoperative, perioperativel and
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postoperative information by a single research assistant. The
use of data and the study was approved by the hospital insti -
tutional review committee.
Liver metastases were diagnosed by contrasted CT scan
or contrasted MRI. Octreotide scan or positron scan (PET)
with DOPA tracer would be performed before consideration
of liver resection [3–6]. Upon diagnosis of liver metastases
patients were assessed by consultant hepatobiliary surgeons
for feasibility of liver resection. In this study, only patients
with lesions that could be completely resected with curative
intention were included. We did not perform debulking liver
resection in this series.
Patients with (1) absence of extrahepatic disease as evi-
dence by octreotide scan or PET scan, (2) lesions which can
be resected completely and (3) good functional reserve with
future liver remnant more than 30% estimated standard liver
mass were selected for liver resection.
We did not perform radiofrequency ablation for NELM
in this series.
Patients with unresectable diseases would be referred to
the oncologist for consideration of non surgical liver directed
surgery or systemic therapy.
All hepatectomies were performed by experienced hepa-
tobiliary surgeons. Open approach was adopted in all twelve
patients. Bilateral subcostal incision with midline extension
was usually used formajor hepatectomy. Intraoperative ultra-
sound was performed during laparotomy. Liver resection
would be carried out only if curative hepatectomy was
feasible. Cholecystectomy was then performed and the cystic
duct was cannulated with an Fr 3.5 Argyle tube before
major hepatectomy. Liver parenchymal transection was per-
formedmainly with the cavitron ultrasonic surgical aspirator
(CUSA). Haemostasis was achieved by electrocautery, argon
beam, and suture. Pringle maneuver for hepatic inflow con-
trol was not routinely performed.Methylene blue leakage test
was performed at the end of major hepatectomy to exclude
biliary leakage after parenchymal transection. Abdominal
drain was not routinely deployed.
Major hepatectomy was defined as removal of more than
3 anatomical sections.
The resected specimens were sent for histopathological
examinations. The tumours were classified into low grade
(<2 mitotic figures/50 hpf), intermediate grade (2–50 mitotic
figures/50 hpf) and high grade (>50 mitotic figures/50 hpf)
[7]. Immunohistochemical staining was performed in some
patients who were operated on in a more recent period. High
Ki-67 staining was defined as abnormal expression >5% [8].
Contrast CT scan was performed one month after the
hepatectomy. The patients were followed up in our clinic at
every 3 months with contrast CT reassessment at the first 2
years and every 6 months with contrast CT scan from third
year after operations. Serum Chromogranin A (CgA) level
and urine 5-hydroxyindoleacetic acid (5-HIAA) level would
be checked in the clinic. Patients were followed up by the
surgeons and the oncologist. Recurrence was defined as typ-
ical features presented on contrast CT/MRI scan on follow-
up. Biopsy of the lesions would be performed if necessary.
The overall survivals and disease-free survivals after the liver
resections were analyzed.
Table 1: Demographic data of patients before hepatectomy.
Variables (𝑛 = 12)
Sex (M : F) 7 : 5
Age (median (range))-liver resection 48.5 (20–71)
HBsAg positive 2 (16.7%)
Serum bilirubin level (umol/L) 8.5 (4–22)
Serum AST 30 (17–203)
Serum ALT 28 (16–65)
INR 1 (0.9–1.2)
Albumin (g/L) 41 (35–46)
PT (second) 12.1 (10.2–14.9)
Creatinine level (umol/L) 80 (58–131)
Hemoglobin level (g/dL) 12.6 (9.3–14.9)
No. of patients with comorbid disease(s) 5 (41.7%)
(i) Cardiovascular disease 9 (75%)
(ii) Pulmonary disease 1 (8.3%)
(iii) Renal impairment 0 (0%)
(iv) Diabetes mellitus 2 (16.7%)
(v) Grave disease 1 (8.3%)
3. Statistical Analysis
The baseline characteristics of patients were expressed as
medians with range. The Mann-Whitney 𝑈 test was used to
compare continuous variables, and a chi-square test was used
to compare discrete variables. Survival curves were computed
using the Kaplan-Meier method and compared between
groups by the log-rank test. Significance was defined as 𝑃 <
0.05. All statistical calculationsweremadewith the SPSS/PC+
computer software (SPSS, Chicago, IL, USA).
4. Results
The median age of the patient was 48.5 years (ranged 20–
71 years). There were seven male patients and five female
patients. Two patients (16.7%) were hepatitis B virus carrier.
Five patients (41.7%) had co-morbid illness before hepa-
tectomy. None of the patient presented with a functional
NELM. The patients’ demographic data is listed in Table 1.
Four patients (33.3%) had minor liver resections for the
NELM. Eight patients (66.7%) had major liver resections for
NELM. The median blood loss was 1.29 L (ranged 0.2–7 L).
Themedian operation time was 418minutes (ranged 195–660
minutes). Pringle maneuver was performed in two patients.
The median inflow control time was 40 minutes (ranged 20–
40 minutes). The median hospital stay was 11 days (ranged
4–56 days). There was no hospital mortality. Three patients
(25%) had complications after hepatectomy. Two patients
developed pleural effusion after the surgery and one of them
required pleurocentesis for symptomatic relieve. One patient
had developed subphrenic collection and required percuta-
neous drainage. The operation details are listed in Table 2.
Six patients (50%) in our series had NELM from pancre-
atic origin; four patients (33.3%) had NELM from unknown
origin; one patient (8.3%) had NELM from adrenal in origin
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Table 2: Operations details of liver resections for NELM.
Variables (𝑛 = 12)
Blood loss (mL) 1.29 (0.2–7.0)
Hospital mortality (%) 0 (0%)
Hospital stay (days) 11 (4–56)
Operation time (minutes) 418 (195–660)
No. of patients with complications 3 (25.0%)
Pleural effusion with tapping 1 (8.3%)
Pleural effusion without tapping 1 (8.3%)
Subphrenic collection with tapping 1 (8.3%)
Clavien Dindo classification
3A 3
3B 0
4A 0
4B 0
5 0
Tumor size (cm) 8.75 (0.9–21.0)
Tumor number
1 6 (50.0%)
3 1 (8.3%)
4 1 (8.3%)
Multiple 4 (33.3%)
Margin size (cm) 0.5 (0.1–1.5)
Margin involved 1 (8.3%)
Presence of microvascular invasion 6 (50%)
and one patient (8.3%) had NELM from colon in origin. The
median tumour size was 8.75 cm (ranged 0.9 cm–21 cm). Six
patients (50%) had one tumour, one patient (8.3%) had three
tumours, one patient (8.3%) had four tumours and 4 patients
(33.3%) had multiple tumours. Eleven patients (91.7%) had
R0 resection and one patient (8.3%) had R1 resection. The
median resectionmargin from the tumour was 5mm (ranged
from 1mm to 15mm). Microvascular invasion was found in
six patients (50%). One patient had high mitotic figure in the
tumour. Five patients had low mitotic figures in the tumours.
Three patients had >5% expression of Ki-67 in the tumours.
The individual patient’s performance is listed in Table 3.
TheMedian follow-up time was 52.8months.Themedian
survival was 52.8months (range 4–57.8months).The one year
survival was 91.7% and the three year survival was 55.6%.
The survival curve is listed in Figure 1.
Themedian disease-free survival was 5.8 months (ranged
1month–51months).The one year and three year disease-free
survival was 33.3% and 16.7%.
The disease-free survival is listed in Figure 2.
Ten possible factors that might affect the survival were
included for univariate analysis and were listed in Table 4.
None of these factors seemed to have adverse effect on overall
survival.
5. Discussion
NELM was a rare disease when compared to colorectal liver
metastases.The nature of history of NELMand the analysis of
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Figure 1: Overall survival of NELM patient after hepatectomy.
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Figure 2: Disease-free survival of NELM patient after hepatectomy.
the best treatment modalities were based on small scale stud-
ies [9–13]. Compared to other metastatic adenocarcinoma of
the liver, NELMs were thought to be more indolent due to
the nature of the disease. But in reality, the 5-year survival
of patients with NELMs on best supportive treatment ranged
from 0% to 20% [1, 2, 14]. The prognosis remained dismal if
no treatment was offered. Awide variety of treatment options
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Table 4: Univariable analysis of factors affecting overall survival.
Median survival (se) 𝑃-value
Age (median)
≤48.5 (𝑛 = 6) 25.11 (10.65) 0.590
>48.5 (𝑛 = 6) 52.84 (27.94)
Sex
Male (𝑛 = 7) 52.84 (0) 0.651
Female (𝑛 = 5) 25.11 (7.04)
Blood loss (median)
≤1.285 L (𝑛 = 6) >51.07 (—) 0.590
>1.285 L (𝑛 = 6) 25.11 (10.65)
Postoperative complication
No (𝑛 = 8) 25.11 (17.47) 0.799
Yes (𝑛 = 3) >51.07 (—)
Magnitude of operation
Major resection (𝑛 = 9) 25.11 (8.94) 0.314
Minor resection (𝑛 = 3) 52.84 (—)
No. of tumors
Solitary (𝑛 = 6) 57.81 (0) 0.072
Multiple (𝑛 = 6) 16.27 (5.22)
Median tumor size
≤5 cm (𝑛 = 5) 16.27 (1.98) 0.327
>5 cm (𝑛 = 7) 52.84 (21.61)
Mitotic Figure
Low (𝑛 = 7) >51.07 0.057
High (𝑛 = 1) 4.042
Microvascular invasion
Absent (𝑛 = 5) >51.07 (—) 0.367
Present (𝑛 = 6) 25.11 (10.65)
Resection margin
R0 resection (𝑛 = 10) 57.81 (0) 0.612
R1 resection (𝑛 = 1) 25.11 (—)
were available including surgical resection, liver directed
therapies, and systemic therapies.
Amongst these treatment options, liver resection seem-
ingly was the most invasive approach. Nevertheless, with
careful patient assessment, the mortality could be less than
5% even in patients with adverse underlying liver parenchy-
mal disease like cirrhosis [15]. The safety of hepatectomy for
noncirrhotic liver was even higher when carried out in high
volume centers [2, 16–18].
In our institution, a thorough liver function evaluation
was strictly followed before consideration of liver resection
[19]. Patients with Child Pugh A liver function, adequate
future liver remnant volume determined by preoperative CT
volumetry and satisfactory indocyanine green (ICG) reten-
tion rate would largely guarantee the safety of liver resection.
Improvements in technologies had also enhanced the safety
of liver resection. The use of pulse spectrophotometry device
allowed a rapid measurement of ICG retention within 6
minutes which is closely correlated to conventional ICG
measurements [20]. Pulse spectrophotometry could also be
performed during the peri-operative period. In addition,
the use of CUSA and new energy devices could enhance
the efficiency of liver transection by reducing the blood
loss. Blood loss was identified to be an important factor
predisposing to hospital mortality in liver resection. Careful
administration of intravenous fluid during the operation
could prevent venous congestion of the liver which could
make liver parenchymal transection less difficult. When
excessive bleeding was encountered, the selective use of
PringleManeuver could be endorsed in an intermittent man-
ner [21]. Inmany patients with NELMs, there weremultifocal
involvements in both lobes of livers. Mayo el at the reported
that more than 47% of patients had more than 50% hepatic
involvement by the metastases upon presentation [2]. The
prognosis of a patient with diffuse liver metastases in general
was poorer when compared to those with less extensive
involvement. In view of this information, patients who
had extensive liver metastases might not be referred for
liver resection. In our study a more aggressive approach to
NELM were adopted. Two-third of the patients in this series
actually had diffuse liver metastases which end up in major
hepatectomy. The best alternative treatment for diffuse
NELMwas intraarterial therapy (IAT).Themost widely used
modality was by transarterial chemoembolisation (TACE).
Since most of the NELMs were rich in arterial supply, TACE
could effectively deliver the chemotherapeutic agent to the
targeted lesions. The femoral artery was catheterised under
local anaesthesia. The right or left hepatic artery was usually
super-selectively catheterized. An emulsion of cisplatin or
doxorubicin with Lipiodol was introduced. After maximal
drug was administrated to the tumour, embolization of the
feeding artery by small gelatine-sponge pellets of 1mm diam-
eter would be introduced [22]. There were very little data on
the outcome of TACE on non-functioning NELM. Mayo et
al. showed that in 66 patients who had non functioning
NELMwith liver involvement >25%, none of the patients had
complete tumour response by RECIST criteria. Only 6.3%
of patients had partial tumour response by RECIST criteria.
Themedian survival for this group of patient was 18.5months
[2]. In our study, despite the fact that more than 60%
of our patient had multifocal NELM, performing major hep-
atectomy in this group of patient by removingmore than 50%
of the liver volumes leaded to a median survival of 52.8
months.
The short term surgical outcome for major liver resection
andminor liver resection was very low. Nearly all the patients
had R0 resection. Only one patient with diffuse NELM had
margin involvement at the histopathology report. Although
high mitotic figures and increased in Ki-67 expression might
provide prognostic value in patients with NELMs in the
literatures, we did notice statistical significance in our current
study. It probably might be due to the relatively small number
of patients being investigated in this series. Rosenau et al.
suggested that a low ki-67 (<5%), e-Cadherin and p53
expression had better survival performance when compared
to those with high Ki-67, e-Caherin and p53 expression in
patients who had undergone liver transplantations [8]. Cho et
al. demonstrated that patients with high grade tumour (>50
mitotic figures at 50x high power field and/or presence of
extensive necrosis) would have poorer survival performance.
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Themedian survival for patients with high grade tumour was
6 months only [23]. The pathological examination of NET
should involve an expert pathologist who had enthusiasm in
performing all these special staining.However, due to scarcity
of this disease, the reporting of these pathological features
was hardly standardized. These special pathological details
were seldom presented in most of the published literatures
[2, 13, 24]. Therefore the importance of these prognostic
indicators should not be over stressed and hindered in the
consideration of radical liver resection. Hepatectomy after all
provided the best hope of cure in patients with resectable
NELMs.
Univariate analysis for potential risk factors affecting sur-
vival was performed in this study. Although none of the fac-
tors demonstrated statistical significance in affecting survival,
factors like tumor number and mitotic activity came close
to meeting significance. We could not demonstrate the
detrimental effect of these two factors because the study was
limited by the relatively small sample number due to rarity
of the disease. High mitotic activates and multifocal liver
metastases might be poor prognostic factors in patients
receiving hepatectomy for NELM.
Since not every patient was a suitable candidate for liver
resection and the tumour response rate varies a lot in IAT,
there had been a lot of enthusiasm in the study of nonsurgical
or nonliver directed therapies. Nonetheless, there was never a
large scale randomized control trial on the treatment of NET
or NELM due to the scarcity of the disease entity. Most of the
evidence was gathered from small scale retrospective studies.
Management of NETs should involve a multidisciplinary
team as different treatment strategices could be employed in
different disease entities and presentations.
6. Conclusion
Hepatectomy is a safe and effective option forNELM.Reason-
able outcome on long term overall survival and disease-free
survival can be achieved with a low morbidity rate.
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